Key Highlights

  • NetraMark Holdings (TSX:AIAI) traded at CAD 0.66 in the October 14, 2026 morning session, up 4.76% on 1.15K shares, or about CAD 759 traded. The prior close of CAD 0.63 followed a 10.00% fall on October 13, 2026.
  • No company release dated October 14, 2026 was found. An August 20, 2026 update reported about CAD 3.42 million of new contracts added in fiscal 2026, against a prior annual high of about CAD 458,000.
  • Revenue for the first nine months of fiscal 2026 was CAD 559,564, up about 45% from CAD 386,085, and about CAD 3.18 million of booked contract value had not yet been recognized as revenue.
  • A private placement for gross proceeds of about CAD 3.5 million closed before the company's TSX uplisting, announced with its May 14, 2026 second-quarter update; unit and warrant terms were not stated in the release.

A Rebound on 1.15K Shares

The advance to CAD 0.66 followed a fall of 10.00% to CAD 0.63 on October 13, 2026, according to published market data, so the 4.76% rise recovers part of that loss. Only 1.15K shares changed hands, about CAD 759 of stock and 0.04 times average volume, which means a few trades can move the price and the print should not be read as buying interest. No company release dated October 14, 2026 was found. The published 52-week range of CAD 0.59 to CAD 1.40 places the quote near the bottom of its band, and the market value is about CAD 58 million. A move of 4.76% equals only three cents, so the quote can flip direction on a single order. The company also trades on the OTCQB, which splits liquidity.

Contracts, Revenue and Funding

NetraMark Holdings sells NetraAI, a platform that analyzes clinical trial data to find patient subgroups that respond to treatment. Customers pay under service contracts, and revenue is recognized as work is delivered, in some cases after trial data readouts, so booked value of CAD 3.737 million can take quarters to convert. Fiscal 2025 revenue was CAD 432,495 with a net loss of about CAD 5.22 million, so operations depend on outside capital. The company uplisted to the Toronto Stock Exchange in 2026 and also trades on the OTCQB under AINMF. Booked contract value is a non-IFRS measure, and the company said it may never convert fully.

Risks and What to Watch

Small customer count, long clinical trial timelines and cash burn are the main risks, and further share issues would dilute holders. The fiscal year ends September 30, so annual results for fiscal 2026 are the next major disclosure, with a published estimate of January 15, 2027 that the company had not confirmed. Investors can also watch new contract announcements. Thin liquidity on the TSX can widen the gap between bid and ask quotes. Nothing in this article is investment advice. Booked contract value is a non-IFRS measure and may not convert to revenue on the timetable investors expect, while customers can delay or cancel analysis work if a trial changes. A fall of 10.00% followed by a 4.76% rebound shows how far a few trades can swing a quote with so little volume.

Where Things Stand

NetraMark Holdings (TSX:AIAI) rebounded 4.76% to CAD 0.66 on 1.15K shares after a 10.00% drop the day before, with no company release dated October 14, 2026 found. Record contract bookings, a CAD 3.5 million placement and ongoing losses are the backdrop. The next catalyst is annual fiscal 2026 results, with a date not yet confirmed by the company. Annual fiscal 2026 results are the first full test of the contract backlog.